283 filings
Page 5 of 15
8-K
bhlw6hi3j8 u60a2hl
25 Oct 19
Advaxis Announces Business and Pipeline Update
12:00am
8-K
v8a3cx6iuo
4 Oct 19
Other Events
4:31pm
8-K
9goj3vr wz
13 Sep 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
oszliv4j0vy75ujjp
9 Sep 19
Advaxis Reports Fiscal Third Quarter 2019 Financial Results and Provides Pipeline Update
4:30pm
8-K
5rur1 ex4i
6 Sep 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
htuub
22 Aug 19
Advaxis, Inc. Issues Letter to Shareholders
4:15pm
8-K
8pg 48sis
31 Jul 19
Material Modifications to Rights of Security Holders
4:15pm
8-K
l3x6ovkdtn3 ps
25 Jul 19
Advaxis, Inc. Announces Pricing of $16 Million Public Offering
5:19pm
8-K
xgk iozbml9f46mtew
15 Jul 19
Other Events
9:38am
8-K
r9ay8cbacqz1p
27 Jun 19
Advaxis Announces Increasing Focus on Neoantigen-Directed Immunotherapies and Closing of its Phase 3 AIM2CERV Study
4:30pm
8-K
4rpwlbdu
10 Jun 19
Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline Update
5:28pm
8-K
og630dfzbd1jm kqdi2
15 May 19
Other Events
10:00am
8-K
sei561k kuhfqsy
13 May 19
Advaxis Announces Appointment of Dr. Robert Petit to Chair of Scientific Advisory Board and Departure as Chief Scientific Officer
4:30pm
8-K
nuiwg
15 Apr 19
Other Events
12:01pm
8-K
aeaz wmny8n88d3yp
5 Apr 19
Entry into a Material Definitive Agreement
4:05pm
8-K
ryj5dreibl2
29 Mar 19
Material Modifications to Rights of Security Holders
4:00pm
8-K
egi ysz6za9e0m
15 Mar 19
Material Modifications to Rights of Security Holders
4:00pm
8-K
0oogxgk6n
14 Mar 19
Entry into a Material Definitive Agreement
9:30am
8-K
ipqehj1
12 Mar 19
Advaxis Reports First Quarter Fiscal 2019 Financial Results and Provides Clinical Pipeline Update
4:30pm
8-K
8vsba3587etrqex
1 Mar 19
Amendments to Articles of Incorporation or Bylaws
1:48pm